ABSTRACT
Objective Childhood immune thrombocytopenia (ITP), an acquired bleeding disorder, occurs at any age. Studies have indicated a less favourable prognosis in children aged above ten years. Low lymphocyte counts have been proposed as predictors of chronic disease. Detailed knowledge of ITP disease characteristics and prognosis at various ages may be useful to support clinical decision-making. We aimed to define how age shapes the clinical characteristics, biological parameters and disease outcomes in childhood ITP.
Design Post-hoc analysis of two prospective European studies (NOPHO ITP study and TIKI trial). Children were followed for 6-12 months.
Setting Patient inclusion in paediatrics departments in the Netherlands and the five Nordic countries.
Patients Children aged <16 years with newly diagnosed ITP (N=577) and severe thrombocytopenia (diagnosis platelet count ≤20 × 109/L).
Results By analysing age effects on a continuous scale, we observed that recovery rates at 3-12 months follow-up were gradually reduced in children aged above five years. An absence of a response to IVIg was observed at all ages, but was more common in older children, in particular above 6 years of age. Leukocyte and lymphocyte subset counts were reduced with age, but not elevated or decreased compared to age-appropriate reference intervals. Children aged below seven years showed elevated thrombopoietin levels.
Conclusions Already from five years of age onwards, there is an increasing risk for a long-lasting course of ITP. Given the varying treatment responses and biological variation, age differences should be considered for the design of clinical trials, prediction models and biological studies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Landsteiner Foundation for Blood Transfusion Research (LSBR); Studienstiftung des Deutschen Volkes.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
For the NOPHO ITP study approval was obtained from the ethical review committees and authorities in each participating country. The TIKI trial was approved by the ethical review committee of University Medical Center Utrecht.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data may be requested from the corresponding author for academic collaborations.
